

Special Issue

Immunology in COVID-19 Disease: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editor

Since December 2019, a novel coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide, causing the coronavirus disease 2019 (COVID-19). Even people with mild symptoms may have long-term sequelae, and it is unknown if these long-term symptoms could be associated with future re-infection or subsequent pathogenesis. Therefore, among the most important questions is that concerning the quality and durability of the immune response after natural infection, which will help develop upcoming vaccines or new therapeutic strategies. This Special Issue aims to include research on the pathophysiological aspects of COVID-19, its immunological features, and possible new therapeutic hypotheses. Particular attention will be given to immune dysregulation both during and after viral infection and new therapeutic approaches. All clinical and basic research, including gender, long-term symptoms, individual clinical background, genetic susceptibility, symptom severity, and mechanistic of viral replication and spreading, will be considered.

Guest Editor

Dr. Marjorie Pion

ImmunoRegulation Laboratory, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

Deadline for manuscript submissions

closed (28 February 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/86142

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).